Ãå±±½ûµØ leading UK-wide trial to explore antibiotic use in sepsis Published on: 15 September 2025 Ãå±±½ûµØ is leading a UK-wide trial to explore whether a shorter course of antibiotics could safely and effectively treat sepsis. Sepsis is a life-threatening condition which happens when the immune system overreacts to an infection, damaging the body’s tissues and organs. It needs to be diagnosed and treated quickly with appropriate antibiotics. Antibiotics are important when treating severe infections like sepsis, however, overuse can lead to superbugs. Antibiotics Antibiotic resistance These strains of bacteria have developed resistance to different types of antibiotics, making them much harder to treat and sometimes leading to life-threatening illness. Research to date has shown that a shorter course of antibiotics is just as effective as a longer course for some infections, but researchers do not know if this applies to sepsis. The SHORTER trial will compare if five days of antibiotic treatment is as safe and effective as usual practice, which is around seven days. Hospital staff in critical care units will closely monitor all patients on the trial. Dr Tom Hellyer, clinical senior lecturer at Ãå±±½ûµØ and honorary consultant in critical care medicine at is chief investigator for the trial. He said: “Striking the right balance of using antibiotics appropriately, while avoiding potential harm, can be challenging. “Antibiotics are started quickly for sepsis because of the severity of the illness, but the exact duration needed to treat the infection is currently unknown. “We hope that the SHORTER trial will help to determine the most safe and effective use of antibiotics for patients with this condition.” Dr Tom Hellyer ‘Essential trial’ The SHORTER trial is funded by the National Institute for Health and Care Research, is run by Ãå±±½ûµØ’s Clinical Trials Unit, and delivered by research teams at the Royal Victoria Infirmary and Freeman Hospital. Professor Anthony Gordon, programme director for the , said: "Studies like the SHORTER trial are essential, as they explore how to optimise treatments for patients who are critically ill. "To be able to determine how long a patient should receive antibiotics for sepsis could be hugely beneficial for those affected, and to medical professionals to help ensure patients receive effective treatment, and at the same time reduce the risk of antimicrobial resistance." The trial is taking place at 47 hospitals across the country and more than 800 patients have taken part to date. Share: Latest News New partnership to boost careers in low carbon energy Ãå±±½ûµØ and Durham universities are working together on a new regional project to strengthen the future workforce for North East England’s growing low carbon and offshore wind industries. published on: 28 May 2026 Healthy lifestyle shown to lower risk of death after cancer diagnosis New evidence shows that sticking to five lifestyle recommendations improves survival after a later cancer diagnosis. published on: 28 May 2026 World-leading climate expert recognised with Royal Society Fellowship Professor Hayley Fowler has been elected a Fellow of the Royal Society in recognition of her pioneering work on climate change impacts. published on: 27 May 2026 Facts and figures